Business Wire

NY-GOLDMAN-SACHS

Share
Goldman Sachs Merchant Banking Division Partners With Leading Data Infrastructure Management Team and Commits up to $500 Million to Form Data Center Platform, Global Compute

The Goldman Sachs Merchant Banking Division (“GS MBD”) today announced that it has partnered with a seasoned management team, led by long-time data center industry executive Scott Peterson, to form Global Compute Infrastructure LP (“Global Compute” or the “Company”), a newly established global data center infrastructure platform.

GS MBD has initially committed to fund up to $500 million of equity capital, primarily from its infrastructure fund, West Street Infrastructure Partners III, LP (“WSIP III”), to enable approximately $1.5 billion in near-term investments deployed across North America, Europe, Asia Pacific and Latin America. Global Compute intends to grow through a combination of acquisitions and organic development to serve customers in geographies with strong secular tailwinds and potential for significant data infrastructure growth. Leveraging the experience and track record of the management team, Global Compute will focus on acquiring and developing facilities which can meet the growing compute, storage, connectivity and colocation deployment needs of the world’s largest technology companies.

The founding Global Compute management team is led by CEO Scott Peterson, the former Chief Investment Officer and co-founder of Digital Realty (“DLR”) with over 18 years of data center industry experience and over 30 years in the real estate investment arena. During his tenure at DLR from 2004 to 2018, Scott led all investment activity and was responsible for $17 billion in total deal volume across both M&A and organic development. Scott is joined by a number of established executives in the data center space; fellow DLR co-founder Christopher Kenney as COO, and former senior DLR executive in EMEA, Stephen Taylor as Head of Europe. Chris was largely responsible for the expansion of DLR’s footprint internationally, and Stephen led many of those initiatives throughout EMEA. The Global Compute team has the specialized experience, deep customer relationships and breadth of capabilities to deliver best-in-class data center infrastructure globally.

Consistent with this strategy, on October 17, 2020, Global Compute signed an agreement to acquire ATM S.A. (“ATM”), the leading data center and communications infrastructure business in Poland from a consortium of funds managed by MCI Capital, the leading technology-focused private equity in CEE, and Mezzanine Management, the leading mezzanine fund in the region. Headquartered in Warsaw, ATM’s world class data center assets, communication infrastructure footprint, customer base and strong reputation in the market provide Global Compute with an attractive entry point into the rapidly growing Central and Eastern European data center market. Global Compute intends to build on ATM’s success and market leadership by positioning the company to service the growing deployment needs of both new and existing customers in Poland and the broader CEE region.

“Goldman Sachs is the perfect partner for us as we pursue global investment opportunities in the data infrastructure space,” according to Scott Peterson, CEO of Global Compute. “Our combined global pedigrees and networks, together with GS MBD’s access to ample growth capital, will allow the Global Compute platform to not only serve the critical needs of our customers around the world, but also create and unlock value for our partners. Our initial investment in ATM S.A. is an ideal illustration of this collaboration. We are extremely enthusiastic about our partnership with Goldman Sachs enabling us to provide creative solutions for our global customers.”

“We are incredibly excited about partnering with Scott and the Global Compute team,” said Leonard Seevers, Managing Director at Goldman Sachs. “We see a tremendous opportunity in the data center space driven by increasing computing and storage demand and we believe the Global Compute team, backed by the global resources of Goldman Sachs, is uniquely positioned to deliver world class solutions to meet that demand.”

GS MBD was advised by Davis Polk & Wardwell LLP. The Global Compute management team was advised by PJT Park Hill and Mayer Brown, while Global Compute was advised by Torch Partners, and White & Case LLP, with respect to the ATM SA acquisition

About Goldman Sachs Merchant Banking Division

Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.

About Global Compute

Global Compute is a new entrant in the data center infrastructure industry. Led by a team of international industry veterans with over 50 years of combined industry experience, the Company intends to acquire, develop and operate data center assets across North America, Europe, Asia Pacific and Latin America. We aim to serve as a partner to the world’s largest technology companies and their customers by providing secure, reliable, and creative solutions for their compute capacity and connectivity requirements in high growth and established markets. Global Compute is backed by the Goldman Sachs Merchant Banking Division.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye